Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro

Anti-Cancer Drugs

Volumn 13, Issue 10, 2002, Pages 1011-1016

  Budman, Daniel R ^a   Calabro, Anthony ^a   Kreis, Willi ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Docetaxel; Median effect analysis; Prostate cancer cell lines; Synergism

Indexed keywords

ACETYLSALICYLIC ACID; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETRORELIX; CISPLATIN; CYCLOSPORIN A; DISULFIRAM; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; HYDROXYFLUTAMIDE; NAVELBINE; PROCARBAZINE; RAZOXANE; RETINOIC ACID; VALSPODAR; VINBLASTINE; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DRUG ANTAGONISM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036865995     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200211000-00005     Document Type: Article

References (36)

1. Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest 1995; 13: 296-312.
2. Kantoff PW, Halabi S, Conaway M, et al. Hydro-cortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-13.
3. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
4. Friedland D, Cohen J, Miller RJr, et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26: 19-23.
5. Kang MH, Figg WD, Dahut W. Taxanes in hormone-refractory prostate cancer. Cancer Pract 1999; 7: 270-2.
6. Kornblith AB, Herndon II, Zuckerman JE, et al. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone-refractory prostate cancer and their partners: A feasibility study. Ann Oncol 2001; 12: 633-41.
7. Kreis W, Budman D. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer. Semin Oncol 1999; 26: 34-8.
8. Oh WK, Kantoff PW. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999; 26: 49-54.
9. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000; 27: 24-9.
10. Small EJ. Docetaxel in prostate cancer. Anti-Cancer Drugs 2001; 12(suppl 1): S17-20.
11. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16.
12. Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: An experimental study. Prostate 2000; 44: 275-8.
13. Kreis W, Budman D, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79: 196-202.
14. Petrylak DP, Macarthur R, O'Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999; 26: 28-33.
15. Savarese D, Taplin ME, Halabi S, et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol 1999; 26: 39-44.
16. Budman D, Calabro A, Kreis W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anti-Cancer Drugs 1998; 9: 687-702.
17. Budman D, Calabro A, Wang L, et al. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro. Cancer Invest 2000; 18: 695-701.
18. Budman DR, Weiselberg L, O'Mara V, et al. A phase I study of sequential vinorelbine followed by paclitaxel. Ann Oncol 1999; 10: 861-3.
19. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41: 665-9.
20. Hartley-Asp B, Gunnarsson PO. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J Urol 1982; 127: 818-22.
21. Chou T, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1988; 115: 207-16.
22. Chou T, Tan Q, Sirotnak F. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemther Pharmacol 1993; 31: 259-64.
23. Loo T, Clarke D. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000; 92: 898-902.
24. Brugnatelli S, Riccardi A, Danova M, et al. Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study. Oncol Rep 2001; 8: 801-5.
25. Earhart RH. Docetaxel (Taxotere): Preclinical and general clinical information. Semin Oncol 1999; 26: 8-13.
26. Miller VA, Krug LM, Ng KK, et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18: 1346-50.
27. Baranwal A, Amjad M, Naidu S, et al. A phase II trial with docetaxel, vinorelbine, and g-csf in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 2001; 20: 2410a.
28. Pagani O, Sessa C, Nole F, et al. Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I-II study. Ann Oncol 2000; 11: 985-91.
29. Sessa C, Pagani O. Docetaxel and epirubicin in advanced breast cancer. Oncologist 2001; 6(suppl 3): 13-6.
30. Brausi M, Jones W, Fossa S, et al. High dose epirubicin is effective in measurable metastatic prostate cancer: A phase II study of the EORTC Genitourinary Group. Eur J Cancer 1995; 31A: 1622-6.
31. Hernes E, Fossa S, Vaage S, et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997; 76: 93-9.
32. Pummer K, Lehnert M, Stettner H, et al. Randomized comparison of total androgen blockage alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 1997: 81-5.
33. Neri B, Barbagli G, Bellesi P, et al. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer. Anticancer Res 1997; 17: 3817-20.
34. Delaere K, Leliefeld H, Peulen F, et al. Phase II trial of epirubicin in advanced hormone-resistant prostatic carcinoma. Br J Urol 1992; 70: 641-2.
35. Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst 2000; 92: 898-902.
36. Kreis W, Budman D Calabro A. A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents. Cancer Chemother Pharmacol 2001; 47: 78-82.